Search by Drug Name or NDC
NDC 62135-0494-30 Ultramicrosize Griseofulvin 125 mg/1 Details
Ultramicrosize Griseofulvin 125 mg/1
Ultramicrosize Griseofulvin is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Chartwell RX, LLC.. The primary component is GRISEOFULVIN.
MedlinePlus Drug Summary
Griseofulvin is used to treat skin infections such as jock itch, athlete's foot, and ringworm; and fungal infections of the scalp, fingernails, and toenails. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.
Related Packages: 62135-0494-30Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Griseofulvin
Product Information
| NDC | 62135-0494 |
|---|---|
| Product ID | 62135-494_06fd3608-5f72-dbcc-e063-6394a90a38a6 |
| Associated GPIs | 11000030200305 |
| GCN Sequence Number | 009520 |
| GCN Sequence Number Description | griseofulvin ultramicrosize TABLET 125 MG ORAL |
| HIC3 | W3A |
| HIC3 Description | ANTIFUNGAL ANTIBIOTICS |
| GCN | 42410 |
| HICL Sequence Number | 004127 |
| HICL Sequence Number Description | GRISEOFULVIN ULTRAMICROSIZE |
| Brand/Generic | Generic |
| Proprietary Name | Ultramicrosize Griseofulvin |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Griseofulvin |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 125 |
| Active Ingredient Units | mg/1 |
| Substance Name | GRISEOFULVIN |
| Labeler Name | Chartwell RX, LLC. |
| Pharmaceutical Class | Decreased Mitosis [PE], Microtubule Inhibition [PE], Tubulin Inhibiting Agent [EPC] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA061996 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 62135-0494-30 (62135049430)
| NDC Package Code | 62135-494-30 |
|---|---|
| Billing NDC | 62135049430 |
| Package | 30 TABLET in 1 BOTTLE, PLASTIC (62135-494-30) |
| Marketing Start Date | 2020-11-30 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |